![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Data)
554kB |
| Item Type: | Article |
|---|---|
| Title: | Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke |
| Creators Name: | Sperber, P.S. and Gebert, P. and Broersen, L.H.A. and Kufner, A. and Huo, S. and Piper, S.K. and Teegen, B. and Heuschmann, P.U. and Prüss, H. and Endres, M. and Liman, T.G. and Siegerink, B. |
| Abstract: | Background: Anti-NMDA-receptor GluN1 antibodies (NMDAR1-abs) are present in an autoimmune encephalitis with severe neuropsychiatric symptoms. We aimed to estimate the impact of serum NMDAR1-abs on depressive symptoms years after first-ever ischemic stroke (IS). Methods: Data were used from the PROSpective Cohort with Incident Stroke-Berlin (PROSCIS-B; NCT01363856). Serum NMDAR1-abs (IgM/IgA/IgG) were measured within 7 days after IS using cell-based assays. We defined seropositivity as titers ≥1:10, thereof low titers as ≤1:100 and high titers as >1:100. We used the Center for Epidemiological Studies–Depression (CES-D) scale to measure depressive symptoms at year one, two and three following IS. We calculated crude and confounder adjusted weighted generalized linear models to quantify the impact of NMDAR1-abs on CES-D assessed at three annual time-points. Results: NMDAR1-abs were measured in 583 PROSCIS-B IS patients (mean age = 67 [SD = 13]; 42%female; median NIHSS = 2 [IQR = 1–4]) of whom 76 (13%; IgM: n = 49/IgA: n = 43/IgG: n = 2) were seropositive, 55 (9%) with low and 21 (4%) with high titers. CES-D regarded over all follow-up time-points was higher in seropositive patients (β(crude) = 2.56 [95%CI = −0.34 to 5.45]; β(adjusted) = 2.26 [95%CI = −0.68 to 5.20]) and effects were highest in patients with high titer (low titers: β(crude) = 1.42 [95%CI = −1.79 to 4.62], β(adjusted) = 0.53 [95%CI = −2.47 to 3.54]; high titers: β(crude) = 5.85 [95%CI = 0.20 to 11.50]; β(adjusted) = 7.20 [95%CI = 0.98 to 13.43]). Conclusion: Patients with serum NMDAR1-abs (predominantly IgM&IgA) suffer more severe depressive symptoms after mild-to-moderate IS compared to NMDAR1-abs seronegative patients. |
| Keywords: | Stroke, Ischemia, Prospective Studies, Receptors, N-Methyl-D-Aspartate, Antibodies, Depression, Humans |
| Source: | Brain Behavior & Immunity - Health |
| ISSN: | 2666-3546 |
| Publisher: | Elsevier |
| Volume: | 34 |
| Page Range: | 100705 |
| Date: | December 2023 |
| Official Publication: | https://doi.org/10.1016/j.bbih.2023.100705 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
